Verberk et al., (2021) found GFAP to be associated with in increased risk of dementia and a sleeper rate of cognitive decline and they conclude that GFAP has the potential to be a prognostic blood-based biomarker for AD in their cohort of cognitively normal older people [18]. This evidence concerns the gene GFAP and Alzheimer disease.